Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | President and CMO | July 14, 2021 | July 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date July 14, 2021 · Filed July 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 726,823 |
Ending reported balance
After 2021-07-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-07-14 · Exercise / conversion · Acquired 34,017 · Balance 760,840 Row 2 · 2021-07-14 · Sale · Disposed 34,017 · Balance 726,823 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2029-02-23 | Direct | 90,983 |
Reported balance
After 2021-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-14 · Exercise / conversion · Acquired 34,017 · Balance 90,983 F2: 25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4
F2: 25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2021 Filed Jul 16, 2021 22:21 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,017 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-046995 · doc4.xml · derivative · entry 3 Rakhit Amit · CIK 0001704636 · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,983 Underlying: Common Stock · 34,017 shares Expires 2029-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 22:21 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | SaleCommon Stock | 34,017 | $3.71 | $126,203.07 |
DisclosureSEC source: 0001209191-21-046995 · doc4.xml · nonDerivative · entry 2 Rakhit Amit · CIK 0001704636 · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,823 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4 Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 22:21 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | Exercise / conversionCommon Stock | 34,017 | $1.89 | $64,292.13 |
DisclosureSEC source: 0001209191-21-046995 · doc4.xml · nonDerivative · entry 1 Rakhit Amit · CIK 0001704636 · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:53 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001209191-20-064665 · doc4.xml · derivative · entry 1 Rakhit Amit · CIK 0001704636 · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on December 17, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:29 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-19-061568 · doc4.xml · derivative · entry 1 Rakhit Amit · CIK 0001704636 · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-12-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on December 18, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 22:46 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001209191-19-055002 · doc4.xml · derivative · entry 1 Rakhit Amit · CIK 0001704636 · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-10-31 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on November 1, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:43 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-19-023200 · doc4.xml · derivative · entry 1 Rakhit Amit · CIK 0001704636 · CMO and PMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-31 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 1, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| February 24, 2019 Filed Feb 27, 2019 02:56 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-013909 · doc4.xml · derivative · entry 1 Rakhit Amit · CIK 0001704636 · CMO and PMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 22:26 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-18-048859 · doc4.xml · derivative · entry 1 Rakhit Amit · CIK 0001704636 · CMO and PMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-08-27 F1 · derivative.exercise_date: The option, representing a right to purchase a total of 70,000 shares becomes exercisable in two equal annual installments beginning on August 27, 2019, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:43 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-18-004912 · doc4.xml · derivative · entry 1 Rakhit Amit · CIK 0001704636 · CMO and PMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2028-01-18 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.